

2

Docket No. MOR-100D2
Serial No. 09/981,639In the Claims

1-13 (canceled)

14 (previously presented). A conductive immunopolymer matrix comprising:

a) a first immunopolymer layer comprising a polyheteroaromatic polymer and an Fc receptor entrapped within said polymer, wherein a first antibody is bound to said Fc receptor in said first polymer; and

b) a second immunopolymer layer comprising a polyheteroaromatic polymer and an Fc receptor entrapped within said polymer, wherein a second antibody is bound to said Fc receptor in said second polymer and said second antibody binds to a determinant or antigen that said first antibody does not bind; and

wherein said first and second immunopolymer layers further comprise a cell monitoring system, wherein said cell monitoring system comprises horseradish peroxidase and glucose oxidase entrapped within said first and second immunopolymers.

15 (previously presented). The conductive immunopolymer matrix according to claim 14, wherein said antibody bound to said Fc receptor of said first immunopolymer layer binds to a CD3, CD4, CD7, CD8, CD10, CD11b, CD14, CD19, CD20, or CD33 determinant.

16 (previously presented). The conductive immunopolymer matrix according to claim 14, wherein said antibody bound to said Fc receptor of said second immunopolymer layer binds to a CD34 determinant.

17 (previously presented). The conductive immunopolymer matrix according to claim 14, wherein said polyheteroaromatic polymer is an alkyl substituted polythiophene or a polypyrrole.

H:\doc\qto\Amid\MOR-100122.2d.doc\DNB\1

3

Docket No. MOR-100D2
Serial No. 09/981,639

18 (previously presented). The conductive immunopolymer matrix according to claim 14, wherein said polyheteroaromatic polymer is a naphthalene sulfonate-doped polypyrrole or a p-toluene sulfonate-doped polypyrrole.

19 (previously presented). The conductive immunopolymer matrix according to claim 14, wherein said polyheteroaromatic polymer has a net negative charge at the surface of said polymer.

20 (previously presented). The conductive immunopolymer matrix according to claim 14, wherein said conductive immunopolymer matrix is provided in a capillary, spiral sheet, or parallel sheet.

21-22 (canceled).

23 (previously presented). The conductive immunopolymer matrix according to claim 14, wherein said first and second immunopolymer layers are sequentially oriented with respect to each other.

24-25 (canceled).

26 (previously presented). A conductive immunopolymer matrix comprising:

- a) a first immunopolymer layer comprising a polyphenol polymer and an Fc receptor entrapped within said polymer, wherein a first antibody is bound to said Fc receptor in said first polymer; and
- b) a second immunopolymer layer comprising a polyphenol polymer and an Fc receptor entrapped within said polymer, wherein a second antibody is bound to said Fc receptor in said second polymer and said second antibody binds to a determinant or antigen that said first antibody does not bind; and

\\:\doc\ptol\amr\MOR-100D2.2d.doc\TND\sl

wherein said first and second immunopolymer layers further comprise a cell monitoring system, wherein said cell monitoring system comprises horseradish peroxidase and glucose oxidase entrapped within said first and second immunopolymers.

27 (previously presented). The conductive immunopolymer matrix according to claim 26, wherein said antibody bound to said Fc receptor of said first immunopolymer layer binds to a CD3, CD4, CD7, CD8, CD10, CD11b, CD14, CD19, CD20, or CD33 determinant.

28 (previously presented). The conductive immunopolymer matrix according to claim 26, wherein said antibody bound to said Fc receptor of said second immunopolymer layer binds to a CD34 determinant.

29 (canceled).

30 (previously presented). The conductive immunopolymer matrix according to claim 26, wherein said polyphenol polymer has a net negative charge at the surface of said polymer.

31 (previously presented). The conductive immunopolymer matrix according to claim 26, wherein said conductive immunopolymer matrix is provided in a capillary, spiral sheet, or parallel sheet.

32-33 (canceled).

34 (previously presented). The conductive immunopolymer matrix according to claim 26, wherein said first and second immunopolymer layers are sequentially oriented with respect to each other.

35-36 (canceled).

5

Docket No. MOR-100D2
Serial No. 09/981,639

37 (previously presented). A conductive immunopolymer matrix comprising a polymer and a molecule having binding specificity for a target molecule, wherein said polymer comprises a polyphenol polymer, and wherein said molecule having binding specificity for a target molecule is an Fe receptor and is entrapped within said polymer.

38 (canceled).

39 (previously presented). The conductive immunopolymer matrix according to claim 37, wherein an antibody is bound to said Fe receptor.

40 (previously presented). The conductive immunopolymer matrix according to claim 37, wherein said polyphenol polymer has a net negative charge at the surface of said polymer.

41 (previously presented). The conductive immunopolymer matrix according to claim 39, wherein said antibody binds to a CD34 determinant.

42 (previously presented). The conductive immunopolymer matrix according to claim 39, wherein said antibody binds to a CD3, CD4, CD7, CD8, CD10, CD11b, CD14, CD19, CD20, or CD33 determinant.

43 (previously presented). The conductive immunopolymer matrix according to claim 37, wherein said conductive immunopolymer matrix is provided in a capillary, spiral sheet, or parallel sheet.

44 (previously presented). The conductive immunopolymer matrix according to claim 37, wherein said conductive immunopolymer matrix further comprises a cell monitoring system, wherein said cell monitoring system comprises horseradish peroxidase and glucose oxidase entrapped within said polymer.

\\:\doc\ptc\Am\1\MOR-100D2.2\doc\DNB\1

6

Docket No. MOR-100102

Serial No. 09/981,639

45 (previously presented). The conductive immunopolymer matrix according to claim 37, wherein said conductive immunopolymer matrix comprises multiple layers of said polymer, and wherein a different antibody is bound to said Fc receptor in each of said layers.

46-59 (canceled).

\\:\doc\p\o\Amd\MOR-100D2 2d.doc(1)NR/s)